3SBio Inc
HKEX:1530
3SBio Inc
3SBio Inc., founded in 1993, is a prominent player in the biopharmaceutical landscape of China. Driven by a mission to improve human health quality through biopharmaceutical innovation, the company has cultivated a robust portfolio of products, primarily focusing on three key therapeutic areas: oncology, nephrology, and autoimmune diseases. At the core of 3SBio's operations is its strong emphasis on research and development, with several state-of-the-art facilities where it continuously explores advancements in biological medicines. These efforts have positioned the company as a leader in the production of recombinant proteins and antibodies, which are essential in treating chronic and life-threatening conditions.
3SBio derives its revenue through a well-integrated business model that spans drug development, manufacturing, and commercialization. This model allows the company not only to generate income from its diverse product offerings but also to leverage strategic partnerships and licensing agreements, both locally and internationally. Their flagship products, such as EPIAO, a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, and TPIAO, a thrombopoietin receptor agonist used in the management of idiopathic thrombocytopenic purpura, are among the top revenue drivers. By maintaining a strong pipeline of both innovative and biosimilar products, 3SBio ensures sustained profitability and growth, meeting the ever-evolving demands of healthcare systems and patients worldwide. Amidst the competitive and rapidly evolving biotech industry, 3SBio stands out with its commitment to quality and innovation, anchored by a strategic vision to expand its influence beyond traditional boundaries.
Earnings Calls
You don't have any saved screeners yet
